Skip to main content

Human LILRB1/CD85j/ILT2 Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB20174

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
MAB20174-100
MAB20174-SP

Key Product Details

Species Reactivity

Human

Applications

Neutralization

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2B Clone # 292327

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant human LILRB1/CD85j/ILT2
Gly24-His458
Accession # Q8NHL6

Specificity

Detects human LILRB1/CD85j/ILT2 in direct ELISAs.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2B

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Human LILRB1/CD85j/ILT2 Antibody

Cell Adhesion Mediated by LILRB1/CD85j/ILT2 and Neutralization by Human LILRB1/CD85j/ILT2 Antibody.

Cell Adhesion Mediated by LILRB1/CD85j/ILT2 and Neutralization by Human LILRB1/CD85j/ILT2 Antibody.

Recombinant Human LILRB1/CD85j/ILT2 Fc Chimera (Catalog # 2017-T2), immobilized onto a microplate, supports the adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line in a dose-dependent manner (orange line), as measured by CalceinAM. Adhesion elicited by Recombinant Human LILRB1/CD85j/ILT2 Fc Chimera (5 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human LILRB1/CD85j/ILT2 Monoclonal Antibody (Catalog # MAB20174). The ND50 is typically 0.05-0.4 µg/mL.

Applications for Human LILRB1/CD85j/ILT2 Antibody

Application
Recommended Usage

Neutralization

Measured by its ability to neutralize LILRB1/CD85j/ILT2-mediated adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line. The Neutralization Dose (ND50) is typically 0.05-0.4 µg/mL in the presence of 5 µg/mL Recombinant Human LILRB1/CD85j/ILT2 Fc Chimera.

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: LILRB1/CD85j/ILT2

The immunoglobulin-like transcript (ILT) family of activating and inhibitory type immunoreceptors are expressed on many leukocyte subsets and function in the regulation of immune responses (1‑3). This family was also named leukocyte Ig-like receptors (LIR) and monocyte/macrophage Ig-like receptors (MIR). ILTs share significant homology with killer cell Ig-like receptors (KIR). The ILT genes are located on human chromosome 19q13.4 in the leukocyte receptor complex, which also include the genes encoding KIRs (4). With the exception of ILT-6, which is a soluble molecule, all ILT family members are type I transmembrane proteins having two or four extracellular Ig-like domains (2, 3). One subset of the ILT receptors (referred to as subfamily B of the LIRs) has long cytoplasmic tails containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that inhibit signaling events by recruiting SH2-containing protein tyrosine phosphatase-1. Another subset of the ILT receptors (referred to as subfamily A of the LIRs) contains activating receptors with short cytoplasmic regions that lack signal transduction motifs. These receptors contain a basic arginine residue within their transmembrane domains, which allows association with Fc R gamma, an immunoreceptor tyrosine-based activation motif (ITAM)-bearing signal adapter protein (1‑3). ILT2, also known as LIR1, MIR7, and CD85j, is expressed on most monocytes, dendritic cells, and mature B cells (1‑3). It is also expressed on small percentages of T cells and NK cells. ILT2 has four extracellular Ig-like domains and three cytoplasmic ITIMs. It functions as an inhibitory receptor that prevents cellular activation. ILT2 has been shown to bind classical (HLA-A and -B) and nonclassical (HLA-G1, -E and -F) MHC class I molecules (MHCI) (1‑3). ILT2 also binds with high affinity to an MHC class I homologue from human cytomegalovirus (3). Ligation of ILT2 by MHC class I may function to poise cellular activation thresholds and inhibit various leukocyte effector mechanisms that are regulated by MHC class I molecules on target cells.

References

  1. Allen, D. et al. (2000) Immunobiol. 202:34.
  2. Colonna, M. et al. (1999) J. Leukocyte Biol. 66:375.
  3. Borges, L. and D. Cosman (2000) Cytokine Growth Factor Rev. 11:209.
  4. Young, N. et al. (2001) Immunogenetics 53:270.

Long Name

Leukocyte Immunoglobulin-like Receptor, Subfamily A (with TM domain), Member 1

Alternate Names

CD85j, ILT2, LIR1, MIR7

Entrez Gene IDs

10859 (Human)

Gene Symbol

LILRB1

UniProt

Additional LILRB1/CD85j/ILT2 Products

Product Documents for Human LILRB1/CD85j/ILT2 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human LILRB1/CD85j/ILT2 Antibody

For research use only

Loading...
Loading...
Loading...